35162-44-8

Basic information

• Product Name: (2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE
• Synonyms: 3',5'-Glyoxyloxylidide,oxime (6CI)
• CAS NO: 35162-44-8
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.21
• Mol File: 35162-44-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.14g/cm³
• Refractive Index: 1.552
• CAS DataBase Reference: (2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE(35162-44-8)
• EPA Substance Registry System: (2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE(35162-44-8)

Safety Data

• Hazardous Substances Data: 35162-44-8(Hazardous Substances Data)

Usage

General Description

The chemical "(2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE" is a compound with the molecular formula C11H14N2O2. It is a derivative of acetamide with a hydroxyimino group attached to the carbon atom. This chemical is also known as N-(3,5-dimethylphenyl)-2-hydroxyimino-2-phenylacetamide and is used in pharmaceutical research and development. The presence of the hydroxyimino group in the compound gives it potential medicinal properties, and it may be explored for its potential as an antiviral or antibacterial agent. It is a white to off-white solid at room temperature and is typically used in laboratory settings for scientific research purposes.

InChI:InChI=1/C10H12N2O2/c1-7-3-8(2)5-9(4-7)12-10(13)6-11-14/h3-6,14H,1-2H3,(H,12,13)/b11-6-

Upstream product

• 302-17-0 chloral hydrate 
• 108-69-0 3,5-dimethylaminoaniline 

Downstream Products

• 90321-33-8 2-amino-4,6-dimethyl-benzoic acid 
• 875241-52-4 2-amino-4,6-dimethyl benzamide 
• 1246250-87-2 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one 

Relevant articles and documents

Further Studies on Triazinoindoles as Potential Novel Multitarget-Directed Anti-Alzheimer's Agents

The inadequate clinical efficacy of the present anti-Alzheimer's disease (AD) drugs and their low impact on the progression of Alzheimer's disease in patients have revised the research focus from single targets to multitarget-directed ligands. A novel series of substituted triazinoindole derivatives were obtained by introducing various substituents on the indole ring for the development of multitarget-directed ligands as anti-AD agents. The experimental data indicated that some of these compounds exhibited significant anti-AD properties. Among them, 8-(piperidin-1-yl)-N-(6-(pyrrolidin-1-yl)hexyl)-5H-[1,2,4]triazino[5,6-b]indol-3-amine (60), the most potent cholinesterase inhibitor (AChE, IC50 value of 0.32 μM; BuChE, IC50 value of 0.21 μM), was also found to possess significant self-mediated Aβ1-42 aggregation inhibitory activity (54% at 25 μM concentration). Additionally, compound 60 showed strong antioxidant activity. In the PAMPA assay, compound 60 exhibited blood-brain barrier penetrating ability. An acute toxicity study in rats demonstrated no sign of toxicity at doses up to 2000 mg/kg. Furthermore, compound 60 significantly restored the cognitive deficits in the scopolamine-induced mice model and Aβ1-42-induced rat model. In the in silico ADMET prediction studies, the compound satisfied all the parameters of CNS acting drugs. These results highlighted the potential of compound 60 to be a promising multitarget-directed ligand for the development of potential anti-AD drugs.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.